Catalytic Asymmetric Synthesis of R207910

摘要

Tuberculosis (TB) is one of the most serious worldwide infectious diseases. Despite the emergence of a multidrug resistant mutant, a new TB drug has not been introduced in the market for more than 40 years. R207910 (1), discovered by the Johnson & Johnson pharmaceutical company, is a promising potent anti-TB drug candidate that selectively inhibits the ATP synthase proton pump of both drug-sensitive and drug-resistant Mycobacterium tuberculosis.